A 2025 prospective cohort of 132 men undergoing VMAT for prostate cancer found that 77% experienced at least one clinically significant intrafraction position shift during their course. Correction was performed in 17% of all treatment fractions.
This is not a planning margin problem. It is a real-time localisation problem — and the only way to detect and correct it is a fiducial that has not moved since Day 1.
Key Numbers — Prostate Evidence
Had ≥1 significant intrafraction position shift
Fiducial detection rate in MRI-only planning (500+ patients)
UTI rate — 621 patients, transrectal approach, thin needle
Marker migration across 626 prostate markers tracked
Peer-Reviewed Evidence
of patients had ≥1 significant position shift · 17% of fractions required correction · n=132
Online correction of intrafraction motion during VMAT for prostate radiotherapy using fiducial-based kV imaging
Journal of Applied Clinical Medical Physics · 2025
fiducial detection success in MRI-only workflow · 500+ patients · simulation time −7.1 days
Development and clinical implementation of an MRI-only planning workflow with deep learning synthetic CT for prostate EBRT
Journal of Applied Clinical Medical Physics (Deng et al.) · 2025
UTI rate across 621 patients (2 cases) · Zero sepsis · Zero hospitalisations
Low Infection Rate After Transrectal Implantation of Gold Anchor Fiducial Markers in Prostate
PMC / Radiation Oncology · 2018
patients over 5 years · 2 early migrations, zero migration throughout RT course
Intra-prostatic Gold Anchor Fiducial Marker Insertion: Five-Year Institutional Experience
BMC Medical Imaging · 2023
Lower cost AND higher QALYs vs competing fiducials — the health-economic optimal choice
Cost-Effectiveness of the Use of Gold Anchor™ Markers in Prostate Cancer
Cureus (Lundqvist & Levin) · 2020
Fluoroscopic tracking of Gold Anchor markers validated for prostate intrafraction management
Real-time nonstandard-shaped Gold Anchor tracking on X-ray fluoroscopic images for prostate radiotherapy
Physics in Medicine & Biology (Sakata et al.) · 2024
DWI artefact — gold fiducial markers do not meaningfully degrade diffusion-weighted MR imaging
Radiotherapy for prostate cancer: Effect of gold fiducial markers on diffusion-weighted MRI
Asia Pacific Journal of Clinical Oncology (Tanaka et al.) · 2021
Gold Anchor used for image guidance in a prospective randomized proton therapy trial
Proton therapy planning and image-guidance strategies within a randomized controlled trial for high-risk prostate cancer
Clinical and Translational Radiation Oncology · 2023
Daily fiducial-based kV guidance with Gold Anchor markers supports prostate PTV margins as low as 5 mm — compared with 10–15 mm required for non-IGRT protocols. This directly reduces dose to rectum and bladder.
MRI-only planning with Gold Anchor fiducials eliminated the need for a separate CT simulation in a 500+ patient series — reducing the time from consultation to start of treatment by an average of 7.1 days.
10-year biochemical failure-free survival of 86.3% and clinical failure-free survival of 86.7% reported in prostate SBRT series using Gold Anchor fiducial-guided delivery. The accuracy of fiducial guidance is integral to these outcomes.
Procedure Demonstrations
Transperineal Prostate Implantation
Dr. Bengt Johansson · Ultrasound-guided transperineal placement for prostate IGRT
Transrectal Prostate Implantation
Dr. Enrique Castellanos · Customer testimonial on transrectal technique
Gold Anchor Placement Guide for Linac-Based RT
Where and how to place markers in prostate for linear accelerator radiotherapy
Saxsons Group supplies Gold Anchor across India with full import documentation, in-service training and ongoing clinical support.
Gold Anchor™
Other Radiation Oncology posts and pages in the Gold Anchor family.
For Radiation Oncologist
When the target moves with every breath, what does it take to get from 5.3 mm soft-tissue alignment error down to 1.5 mm?
Read this Radiation OncologistRoughly one in five standard coil markers migrate in lung parenchyma. What changes with a fold-anchor design and a thinner needle?
Read this Radiation OncologistWhat is the proton-fluence perturbation at clinical energies — and how do Gold Anchor fiducials compare to gold cylinders and titanium markers?
Read this Radiation OncologistA single-page overview of where the published evidence sits for prostate, liver, lung and particle therapy.
Read this